TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00079001
Drug: androgen deprivation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients concurrently enrolled on the Phase III study of intermittent androgen deprivation in patients with stage D2 prostate cancer will receive androgen deprivation therapy per SWOG-9346. All other patients will receive androgen deprivation therapy at a standard dose and schedule throughout the study.
Study: NCT04301869
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral versus intravenous therapy
Study: NCT00815542
Drug: prostaglandins E2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: prostaglandins E2 - Intravaginal Propess for 24 hours
Study: NCT01040637
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascending doses
Study: NCT04463251
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline (0.9% Sodium Chloride solution for Injection), 2 mL in the 4-mL transparent glass vial
Study: NCT02173665
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02700373
Drug: PDC-APB
Normalized name: chlorpheniramine maleate / dihydrocodeine bitartrate / phenylephrine hydrochloride Oral Solution [Despec-PDC]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01868022
Drug: GSK3052230
Approvals — FDA: no, EMA: no, PMDA: no
Description: A clear to opalescent, colorless to pale yellow solution for IV infusion once weekly (Day 1, Day 8, Day 15) in each 21-day cycle with unit dose strengths/dose level of 5, 10, 15, and 20 mg/kg supplied in a sterile 25 mL glass vial.
Study: NCT03640390
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group will receive normal saline infusion
Study: NCT04397497
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching volume of diluent
Study: NCT03318497
Drug: 3'-deoxy-3'-[F-18] fluorothymidine: [F-18]FLT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV The experimental 18F-FLT-PET/CT is required to be completed before initiation of chemotherapy. Labs and correlative radiology, as directed per clinical care, are required within 30 days prior to 18F-FLT-PET/CT; and 18F-FDG-PET/CT is required within 30 days before the 18F-FLT-PET/CT. Follow-up will comprise 24 months of standard practice treatment and follow up.
Study: NCT03625466
Drug: LUM/IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC tablets or granules for oral administration.
Study: NCT03625466
Drug: LUM/IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC granules for oral administration.
Study: NCT01575834
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection once a month (QM)
Study: NCT01927315
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Placebo tablets once daily
Study: NCT02846181
Drug: [14C]-SK-1405
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02346357
Drug: Placebo Saline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00690677
Drug: LBH589
Approvals — FDA: no, EMA: no, PMDA: no
Description: LBH589 will be administered orally at a dose of 30mg (1 - 20mg capsule and 2 - 5g capsules) on Monday, Wednesday and Friday of each week (three times a week). Patients may continue treatment with oral LBH589 until they experience unacceptable toxicity that precludes further treatment, disease progression, and/or at the discretion of the investigator.~The LBH589 capsules should be swallowed by mouth with a glass of water in the morning. The recommended way to take LBH589 is after not eating for at least 2 hours. You should also not eat for another 2 hours after taking your LBH589 capsules. The daily dose of LBH589 should be taken at approximately the same time each day. You should avoid eating grapefruit, seville oranges, or drinking grapefruit or seville orange juice during the study.
Study: NCT03839862
Drug: TNF-inhibition
Normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initiation of immunosuppression with any TNF-inhibitor, e.g. infliximab, etanercept or adalimumab
Study: NCT04305457
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric Oxide (NO) will be delivered together with the standard of care for a period of 20-30 minutes 2 times per day for 14 consecutive days from time of enrollment. Targeted No inhaled concentration will be maintained between 140 and 180 ppm. The gas will be delivered through a CPAP circuit ensuring an end-expiratory pressure between 2 and 10 cmH2O or through a non-rebreathing mask without positive end-expiratory pressure, depending on the clinical needs of the subject.
Study: NCT01566539
Drug: Intranasal Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo sprays that are pH adjusted to comparable levels of the drugs given. Five puffs per nostril; ten puffs total.
Study: NCT03259425
Drug: HF10
Normalized name: Hydrofluoric Acid 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 107th TCID50/mL, intratumoral injection to a single or multiple eligible tumors for a total of 5 mL; on days 0, 7, 14, 21, 28, 42, 56, 70, 84 for a total of 9 injections. All eligible tumors except one will be treated with HF10 up to the maximum volume allowed. The untreated tumor will be used as an untreated control lesion.
Study: NCT02049905
Drug: Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02728505
Drug: SinuSurf irrigation twice daily
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02728505
Drug: NeilMed Sinus rinse irrigation twice daily
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00542009
Drug: CE-326,597 100 mg QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally, once daily with morning meal for duration of trial (84 days).
Study: NCT00542009
Drug: CE-326,597 50 mg QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally, once daily with morning meal for duration of trial (84 days).
Study: NCT00542009
Drug: CE-326,597 25 mg QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally, once daily with morning meal for duration of trial (84 days).
Study: NCT00542009
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match CE-326,597 tablets to be administered orally, once daily with morning meal for duration of trial (84 days).
Study: NCT00542009
Drug: CE-326,597 5mg QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally, once daily with morning meal for duration of trial (84 days).
Study: NCT02892110
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg daily
Study: NCT00267969
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form = solution for injection, route = SC administered at Weeks 0 and 4. At Weeks 12 and 16, placebo will be crossed over to receive ustekinumab 45 mg or 90 mg.
Study: NCT01665157
Drug: low volume 1.5L PEG-ELS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low volume PEG-ELS
Study: NCT02022280
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin pill
Study: NCT03766867
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: concentrate for solution for infusion, 25 mL administered in 250 mL saline over 2 hours as single dose
Study: NCT03766867
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration once daily
Study: NCT02619864
Drug: AZD2014
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02390921
Drug: Fisiogen Ferro Forte
Normalized name: Ferro-Sequels
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients will interrupt the endovenous treatment with iron and will receive liposomated iron 28mg/daily during 3 months.
Study: NCT00893412
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03243032
Drug: Ibuprofen 600 mg
Normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 600mg given 30 minutes prior to beginning of surgery
Study: NCT03243032
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Microcrystalline Cellulose NF (Avicel PH 105) - compounded at the University of Iowa College of Dentistry Pharmacy) given 30 minutes prior to beginning of surgery
Study: NCT03243032
Drug: Local anesthetic Control
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine with 1:100,000 epinephrine as the local anesthetic for Group 2 - Control
Study: NCT00650013
Drug: ProAmatine® Tablets 5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg, single dose fed
Study: NCT01392924
Drug: SAR245408
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet Route of administration: oral
Study: NCT01152346
Drug: Vidaza®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg/m2 sc injection on Day 1 of either cycle 1 or cycle 2 per randomization assignment
Study: NCT00005891
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02115581
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: dose of 2 mg/kg/day in 2 or 3 divided doses and increased to the maximum dose of 10 mg/kg/day according to the patient's tolerance
Study: NCT01839214
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00305084
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m² intravenous infusion over 15 minutes (starting 1 hour after the end of NGR-hTNF infusion)
Study: NCT02555150
Drug: PRC-063
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral extended-release capsule
Study: NCT02555150
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo capsule
Study: NCT01873404
Drug: BG00010
Approvals — FDA: no, EMA: no, PMDA: no
Description: As specified in the treatment arm
Study: NCT01873404
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: As specified in the treatment arm
Study: NCT01046903
Drug: Fragmin® (Dalteparin Sodium)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered per prescribing physician
Study: NCT02329379
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00996151
Drug: Testosterone MD-Lotion
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose Testosterone MD-Lotion 2%
Study: NCT02508077
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02508077
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT03046589
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: control to dose-escalation
Study: NCT02523976
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02523976
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00613964
Drug: Carperitide heart failure therapy
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: carperitide(alpha-human atrial natriuretic peptide, 0.025-0.05μg/kg/min)
Study: NCT00613964
Drug: Standard heart failure therapy
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loop diuretics, Aldosterone blockers, Beta blockers, ACE inhibitors, Angiotensin receptor blockers, Nitrates, digitalis
Study: NCT00554918
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01240577
Drug: IPdR
Normalized name: DripDrop
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00554918
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02607774
Drug: AIN457
Approvals — FDA: no, EMA: no, PMDA: no
Description: secukinumab administered at Weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24
Study: NCT04161404
Drug: Brand name: Andrographis paniculata (Shine Hempedu Bumi) 1000mg capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Andrographis paniculata or hempedu bumi capsule is a traditional medicinal product registered under Ministry of Health Malaysia for general wealth being. It is traditionally used for anti-diabetic, anti-bacterial, anti-pyretic, anti-malarial, anti-inflammatory, antidiarrhoeal and other effects.
Study: NCT00004237
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004237
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02737254
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 0,9 % nasal spray.
Study: NCT05533008
Drug: CR845 0.5 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV CR845 0.5 mcg/kg as a bolus injection
Study: NCT00294372
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04232917
Drug: 2LPAPI®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment
Study: NCT04232917
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03486080
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo control
Study: NCT00708552
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparator
Study: NCT01223625
Drug: Rosuvastatin 5mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 5mg/day
Study: NCT01223625
Drug: Rosuvastatin 40mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 40mg/day
Study: NCT03867136
Drug: PZA sensitivity guided ultra-short all Oral Regimen
Normalized name: aspirin Oral Tablet [Anacin Aspirin Regimen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrazinamide 1500 mg daily; Levofloxacin ≤50kg 500 mg daily, \>50kg 750mg daily; Linezolid: 600 mg daily; Cycloserine ≤50kg 500 mg daily, \>50kg 750mg daily; Clofazimine 100 mg daily; All treatment is taken daily;
Study: NCT03867136
Drug: Standardized Shorter Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrazinamide 1500 mg daily;Levofloxacin 400 mg daily,; Prothionamide ≤50kg 500 mg daily, \>50kg 750mg daily; Ethambutol: ≤50kg 750 mg daily, \>50kg 1000mg daily; Clofazimine: 100 mg daily; Amikacin 600mg daily; High-dose isoniazid 600mg daily. All treatment is taken daily.
Study: NCT05473949
Drug: Profofol for Sedation in Cholangiopancreatography for ASA III and ASA IV Patients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of 1% Propofol (Indution dose: 0.75mg/kg Maintenance dose: 6-7mg/kg/h) for Sedation in Cholangiopancreatography for ASA III and ASA IV Patients
Study: NCT05473949
Drug: Ketofol for Sedation in Cholangiopancreatography for ASA III and ASA IV Patients
Approvals — FDA: no, EMA: no, PMDA: no
Description: use of Ketofol (1% Propofol + 5% Ketamine with a ratio 1/4) Indution dose: 0.75mg/kg Maintenance dose: 6-7mg/kg/h) for Sedation in Cholangiopancreatography for ASA III and ASA IV Patients
Study: NCT00603902
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablet each morning and evening for a duration of 52 weeks.
Study: NCT00981214
Drug: EUR-1008 (APT-1008)
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EUR-1008 (APT-1008) Microtabs contained in a capsule will be administered orally from Day 5 to Day 11 at an enzyme dose based on investigator's discretion, in dose stabilization period or the content of the capsule will be allowed to sprinkle on food, where necessary, followed by stabilized dose from Day 12 to Day 18 in treatment period, up to a maximum total dose of 10,000 lipase units per kilogram body weight per day (unit/kg/day).
Study: NCT00675012
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: orally 825 mg/sqm 2qDx14
Study: NCT03079141
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive 25 milligrams oral eplerenone once daily for a week, and - when no abnormalities during blood testing for potassium and renal clearance can be detected both before treatment and during the first week of treatment - will receive 50 milligrams oral eplerenone for another 11 weeks thereafter.~When patients are randomized to the eplerenone arm of this study, they will receive this treatment as a first cCSC treatment. Moreover, eplerenone treatment can be initiated in patients in whom SRF is still present on OCT at the Evaluation Visit at 3 months after PDT treatment.
Study: NCT01125241
Drug: wuling capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally, three tablets each time,three times a day
Study: NCT01125241
Drug: placebo of wuling capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally, three tablets each time and three times a day
Study: NCT00003118
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003113
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide are given on days 22-31 of each cycle.
Study: NCT00243295
Drug: rhBMP-2/CPM
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00707681
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4ml/vial
Study: NCT00032149
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00032149
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02529449
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT02529449
Drug: ASP1941
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT03318978
Drug: [14C]-benzo[a]pyrene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral micro-dose range (25, 50, 100 and 250 ng)
Study: NCT01224093
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: as prescribed
Study: NCT02760823
Drug: Placebo (for Alpha Lipoic Acid)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline in syringe simulating Alpha Lipoic Acid 600mg
Study: NCT00610155
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID
Study: NCT01488136
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose Ph capsules (Placebo)
Study: NCT03882983
Drug: Antria Cell Preparation Process
Normalized name: Bos taurus red blood cell preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological/Vaccine: Stromal Vascular Fraction The SVF obtained from adipose tissue will be added to the graft~Other Names:~* Stromal Vascular Fraction~* Adiployx Biological/Vaccine:
Study: NCT02337608
Drug: GLPG1205
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG1205 daily dosing in the morning for 12 weeks
Study: NCT02337608
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo daily dosing in the morning daily for 12 weeks
Study: NCT01254123
Drug: Placebo infusion.
Approvals — FDA: no, EMA: no, PMDA: no
Description: On arrival to our cardiac care unit (CCU) and after informed consent patients will be randomized to Exenatide infusion or Placebo infusion. Patients in the placebo group will immediately be treated with placebo infusion.~Placebo preparation: 49ml saline and 1ml Human Serum Albumen (Cealb 200g/L, 10ml) to get a total of 50 ml will be placed in a 50cc syringe and placed in a pump system that is connected with a cannula in the patient's vein. The infusionrate will be 33,3 ml/hr for the first 30 minutes, followed by an infusion rate of 2,8 ml/hr for 72 hours. New 50cc syringes will be made every 8 hours.
Study: NCT04988932
Drug: Inhaled nitric oxide
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each increase of iNO dose is followed by a 10-minute monitoring period and a DSA examination. After reaching the highest effective dose of iNO or the maximum of 40 ppm another DSA is performed. iNO is going to be continued until normalisation of CVS or for a maximum period of 5 days. During iNO treatment a DSA will be performed every 24 hours, followed by a decrease of iNO to the next-lower level. If tapering the iNO concentration is associated with increasing vasospasm, iNO is going to be increased again to the last effective dosage. For cessation of iNO administration, dosage will be tapered every 30 minutes using the same dosage steps as for initiation of iNO treatment. If the duration of iNO treatment will be more than 32 hours, tapering intervals are prolonged to 4 hours. Cessation of iNO will be followed by a DSA.
Study: NCT02739009
Drug: MOR106 single ascending doses, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02739009
Drug: Placebo single ascending doses, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02739009
Drug: MOR106 multiple ascending doses, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02739009
Drug: Placebo multiple intravenous administrations
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01073605
Drug: Genotonorm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7 IU/kg/week or 0.03 mg/kg/day, daily subcutaneous injection
Study: NCT03491462
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 matched placebo capsules taken 3 times daily
Study: NCT02507648
Drug: Tamiflu®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet contains 75 mg oseltamivir
Study: NCT04364230
Drug: NeoAg-mBRAF
Normalized name: B-Raf serine-threonine kinase (BRAF) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRAF 586-614 (V600E) peptide to which a histidine has been added to the N-terminus, resulting in BRAF 585-614 (V600E).
Study: NCT02582892
Drug: Vit D
Normalized name: Tri-Vit Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day
Study: NCT01288196
Drug: Placebo IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single 30-minute IV infusion of placebo
Study: NCT01288196
Drug: CNTO 6785 1 mg/kg IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single 30-minute IV infusion of CNTO 6785 1 mg/kg
Study: NCT01288196
Drug: CNTO 6785 3 mg/kg IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single 30-minute IV infusion of CNTO 6785 3 mg/kg